Form D · Biotechnology

Alucent Biomedical, Inc.

Salt Lake City, UT · CIK 0001631834

Offering snapshot reported Apr 20, 2023 · SEC filing

Reported sold
$11.2M
Offering amount: $11.2M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 17, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 20, 2023Initial$11,200,000No comparison1SEC filing
Oct 15, 2020Initial$34,999,999No comparison3SEC filing
Jan 27, 2015Initial$400,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-479597

Source: Form D, filed Apr 20, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Corbett Director
Pat Costello Director
Michael Elliot Director
David Flicek Director
Myles Greenberg Director, Executive
Ryan Hansen Director
Henry Hauser Executive
James Isaacson Executive
Colin Jackson Executive
David Kapaska Director
Katalin Kauser Executive
Bruce Krattenmaker Executive
Julie Lautt Director
Scott Mayfield Executive
Julie Norton Director
Nick Pappas Director
Daniel Pelak Director
Dan Pelak Director
Fred Slunecka Director
Kevin Warner Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
675 Arapeen Drive, Suite 102
Salt Lake City, UT, 84108